echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Antidepressant "Futhioxetine" Chia Tai Tianqing receives first copy approval

    Antidepressant "Futhioxetine" Chia Tai Tianqing receives first copy approval

    • Last Update: 2021-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 23, NMPA issued an approval document, and Chia Tai Tianqing’s 4 generic generic drug "Futhioxetine" was approved for marketing, becoming another first generic drug of "The King of First Generics", which is an antidepressant drug


    Futhiaxetine hydrobromide tablets (Xindayue®), developed by the Danish Lingbei company; In 2013, Xindayue® was approved by the U.


    According to the Insight database, there are currently 7 domestic companies that declare vothiaxetine


    Futhiaxetine variety competition details (Insight)

    From the Insight database (http://db.


    As one of the most common mental illnesses in China, the prevalence of depression reaches 4.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.